Get the Stockscreener App
6.09
16.44%
0.86
After Hours:
6.08
-0.010
-0.16%
Recursion Pharmaceuticals Inc stock is traded at $6.09, with a volume of 93.53M.
It is up +16.44% in the last 24 hours and up +31.82% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$5.23
Open:
$5.25
24h Volume:
93.53M
Relative Volume:
3.45
Market Cap:
$2.60B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-3.929
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
+19.41%
1M Performance:
+31.82%
6M Performance:
+53.40%
1Y Performance:
-5.43%
1-Day Range:
$5.19
$6.30
1-Week Range:
$5.11
$6.30
52-Week Range:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
6.09 | 2.28B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
What's Going On With Recursion Pharmaceuticals Stock On Wednesday? - Benzinga
Recursion Pharmaceuticals Shares Surge Amid Strategic Growth - TipRanks
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025 - ts2.tech
Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know - Nasdaq
RXRX Shares Plunge: Time to Bail Out? - StocksToTrade
Needham Reiterates a Buy on Recursion Pharmaceuticals (RXRX) - MSN
Can Recursion Pharmaceuticals Inc. recover in the next quarterJuly 2025 Analyst Calls & Safe Capital Allocation Plans - newser.com
Custom strategy builders for tracking Recursion Pharmaceuticals Inc.2025 Trade Ideas & Weekly Watchlist for Hot Stocks - newser.com
How to recover losses in Recursion Pharmaceuticals Inc. stock2025 Market Sentiment & Verified Technical Trade Signals - newser.com
Is Recursion Pharmaceuticals Inc. still worth holding after the dip2025 Growth vs Value & Fast Exit Strategy with Risk Control - newser.com
Will Recursion Pharmaceuticals Inc. stock recover faster than market2025 Big Picture & Entry and Exit Point Strategies - newser.com
Should you wait for a breakout in Recursion Pharmaceuticals Inc.Trade Entry Summary & Real-Time Buy Zone Alerts - newser.com
Biotech Stocks To Watch NowOctober 4th - MarketBeat
Why Recursion Pharmaceuticals (RXRX) Is Up 19.2% After Securing $12.5M Milestone in AI Drug Partnership - simplywall.st
Biotech Stocks To ResearchOctober 3rd - MarketBeat
Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains? - Yahoo Finance
Evaluating Recursion After a 19% Rally Amid Renewed Interest in Biotech AI Initiatives - Yahoo Finance
Recursion Pharmaceuticals (RXRX): Assessing Valuation Following New Milestone Payment and Drug Development Progress - simplywall.st
Smart tools for monitoring Recursion Pharmaceuticals Inc.’s price actionWeekly Profit Summary & Weekly Momentum Picks - newser.com
Published on: 2025-10-03 01:30:40 - newser.com
Published on: 2025-10-02 22:53:16 - newser.com
Recursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 Acquisition - MSN
Best Biotech Stocks To Watch NowOctober 2nd - MarketBeat
Recursion Pharmaceuticals Inc. (RXRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
RXRX’s Market Moves: A Deep Dive - timothysykes.com
Recursion Pharmaceuticals’ Bold Strategy: A Gamechanger? - StocksToTrade
Recursion Pharmaceuticals Stock (RXRX) Opinions on $12.5M Milestone Payment - Quiver Quantitative
Published on: 2025-09-30 19:47:45 - newser.com
Jim Cramer on Recursion: “I Need to See a Proof of Concept Here” - MSN
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years - AOL.com
Recursion Pharmaceuticals’ Recent Moves: What’s Next? - timothysykes.com
Recursion Pharmaceuticals’ Unexpected Surge - StocksToTrade
Recursion’s New Moves: Market Shake-Up? - timothysykes.com
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):